Global Thyroid Cancer Drugs Market

Global Thyroid Cancer Drugs Market Outlook

The global thyroid cancer drug market is majorly driven by the increasing prevalence rate of neuroendocrine tumors worldwide. The increasing rate of thyroid cancer among women is also likely to drive the market. According to the American Cancer Society, about 52,070 new cases of thyroid cancer will be found in the USA in 2019 and an estimated 2,170 deaths will occur because of the disease. Moreover, the surging demand of treatment and novel therapies and rising awareness about the treatment and technological advancements are further projected to foster the growth of the market. Growing cases of obesity and adopting an unhealthy lifestyle is another factor expected to boost market growth. On the other hand, patent expiry of patented drugs and the introduction of a generic version of branded drugs is the key factor that might hinder the growth of the global market. Furthermore, inadequate awareness regarding thyroid cancer treatment is also restricting market growth. 

Global Thyroid Cancer Drugs Market Competitive Landscape 

The Global Thyroid Cancer Drugs Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as AstraZeneca, Mylan N.V., Eisai Co., Ltd., Bristol-Myers Squibb Company, Abbott, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Jerome Stevens Pharmaceuticals, Inc, Baxter, Celgene Corporation.

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.